New Platform for Accelerated Development of Biological Drug Molecules to be Launched by Catalent at BIO International Convention

Share Article

Catalent Pharma Solutions [booth #5544], the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products, today announced that it is extending its OptiForm® Solution Suite technology platform to introduce rapid screening of macromolecules’ suitability for non-invasive drug delivery. The company’s new OptiForm® Solution Suite Bio will be launched at the upcoming BIO International Convention, to be held at the Moscone Center, San Francisco, CA, between the 6th and 9th of June, 2016.

Catalent Pharma Solutions [booth #5544], the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products, today announced that it is extending its OptiForm® Solution Suite technology platform to introduce rapid screening of macromolecules’ suitability for non-invasive drug delivery. The company’s new OptiForm® Solution Suite Bio will be launched at the upcoming BIO International Convention, to be held at the Moscone Center, San Francisco, CA, between the 6th and 9th of June, 2016.

OptiForm Solution Suite was launched in 2015, and combines both predictive and high throughput screening technologies to identify the most stable and efficient drug form for small molecules. Expanding the scope of the solution to encompass macromolecules, OptiForm Solution Suite Bio employs Catalent’s OptiGel™ Bio and Zydis® Bio advanced formulation technologies, and uses a parallel screening model, based on rigorous science and best-in-class formulation expertise, to deliver in vivo study material in as little as three weeks. OptiForm Solution Suite Bio offers developers an easy, cost effective approach for macromolecule oral dose development.

Additionally, Catalent has a number of expert speakers presenting at the BIO Convention, including:

  •     At 2.00 p.m. on Tuesday, June 7, Julien Meissonnier, VP Science and Technology will present “Optimizing non-invasive delivery of biomolecules” at the BioProcess International Theater;
  •     On Wednesday, June 8, at 1.40 p.m., also at the BioProcess International Theater, Michael Merges, Director of Catalent Biologics, will be discussing “Benefits to Strategic Outsourcing of Biologics Analytical Studies”;
  •     Finally, Andrew Sandford, VP Global Business Development Biologics, has been invited along with executives from Cook Pharmica and Pfizer CentreOne to participate in a roundtable chaired by The Pharma & Biopharma Outsourcing Association (PBOA), which will take place on Wednesday, June 8, at 1.30 p.m.

Catalent will also be showcasing a number of its advanced development and manufacturing solutions during the show, including its proprietary GPEx® cell line engineering technology, a proven development tool for stable, high performance cell lines, and SMARTag™ technology, a new toolkit to develop optimized antibody-drug conjugates and bioconjugates.

For more information on the upcoming BIO International Convention event visit: http://www.catalent.com/index.php/news-events/events/BIO-International

To arrange a meeting with Catalent executives at these events, contact Richard Kerns at NEPR- richard(at)nepr.eu.

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Halling

Richard Kerns
Northern Exposure PR
+44 7974 579202
Email >
Visit website